Study guide

7.4 Medication Reconciliation, Adjunct Agents, and Drug-Level Monitoring

AAHFN Certified Heart Failure Nurse CHFN

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Patient History, Risk Factors, and Etiologies

1.1 Heart Failure Etiologies, Risk Factors, and Comorbid Conditions 1.2 Clinical History Taking, Social Determinants of Health, and Device History 1.3 Recognizing Signs and Symptoms of Heart Failure Decompensation

2 Chapter 2: Physical Examination and Hemodynamic Evaluation

2.1 Physical Assessment of Volume and Congestion Status 2.2 Physical Assessment of Perfusion and Low-Output States 2.3 Hemodynamic Profiling and Invasive Hemodynamics

3 Chapter 3: Laboratory Biomarkers and Diagnostic Testing

3.1 Natriuretic Peptides: BNP and NT-proBNP in Clinical Practice 3.2 Essential Laboratory Panels: Renal, Electrolyte, Hepatic, and Iron Evaluation 3.3 Diagnostic Imaging, ECG, and Device Interrogation

4 Chapter 4: Classification, Staging, and Functional Assessment

4.1 ACC/AHA Stages and LVEF Phenotypes 4.2 NYHA Functional Classification, 6-Minute Walk, and Quality-of-Life Measures 4.3 Frailty, Orthostatic Hypotension, and Age-Friendly Care Frameworks

5 Chapter 5: Individualized Care Planning and Shared Decision-Making

5.1 Care Setting Determination and Acuity Stratification 5.2 Formulating Etiology-Directed and Comorbidity-Integrated Goals 5.3 Shared Decision-Making, Patient Preferences, and Social Determinants

6 Chapter 6: GDMT Pharmacotherapy for HFrEF

6.1 The Four Pillars of GDMT: ARNI/ACEi/ARB, Beta-Blockers, MRA, and SGLT2i 6.2 Second-Line and Specialized Pharmacotherapy: Ivabradine, Vericiguat, Digoxin, and Hydralazine-Nitrates 6.3 Medications to Avoid and Drug Safety in Heart Failure

7 Chapter 7: Diuretics, HFpEF, Comorbidity Pharmacotherapy, and Medication Safety

7.1 Diuretic Strategies: Loop Diuretics, Conversions, and Sequential Nephron Blockade 7.2 Management of Heart Failure with Preserved (HFpEF), Mildly Reduced (HFmrEF), and Improved Ejection Fraction (HFimpEF) 7.3 Comorbidity-Directed Pharmacotherapy: Iron Repletion, Anticoagulation, and Immunizations 7.4 Medication Reconciliation, Adjunct Agents, and Drug-Level Monitoring

8 Chapter 8: Device Therapy, Rhythm Management, and Advanced Interventions

8.1 Implantable Devices: ICD and CRT Indications, Titration, and Screening 8.2 Advanced Heart Failure Therapies: Inotropes, Mechanical Circulatory Support (LVAD), and Heart Transplantation 8.3 Ambulatory Hemodynamic Monitoring and Ultrafiltration

9 Chapter 9: Patient Education, Self-Care, Screening, and Referrals

9.1 Self-Care Education and Daily Weight Monitoring 9.2 Dietary Sodium, Fluid Management, and Lifestyle Modifications 9.3 Exercise Prescription, Cardiac Rehabilitation, and Health Literacy 9.4 Individualized Teaching Plans and Learning Methods 9.5 Comorbidity Screening, Stress Management, and Referral Pathways

10 Chapter 10: Therapy Effectiveness, Monitoring, and Care Transitions

10.1 Monitoring and Titration Evaluation: GDMT Tolerance, Lab Trends, and Hemodynamics 10.2 Outpatient and Remote Monitoring Systems 10.3 Post-Acute Care Transitions and Preventing 30-Day Readmissions

11 Chapter 11: Patient Comprehension, Self-Care Adherence, and Palliative Transitions

11.1 Evaluating Patient and Caregiver Education Comprehension 11.2 Identifying and Addressing Adherence Barriers 11.3 Palliative Care, Goals of Care, and End-of-Life Device Management

12 Chapter 12: Professional Standards, Ethics, Quality, and Certification

12.1 Legal Parameters, Ethical Principles, and Patient Advocacy 12.2 Interdisciplinary Collaboration, SBAR Communication, and Care Coordination 12.3 Evidence-Based Guidelines, Quality Improvement, and Addressing Disparities 12.4 Certification, Continuing Education, and Professional Development

7.4 Medication Reconciliation, Adjunct Agents, and Drug-Level Monitoring

Key Takeaways Explain This Topic AI

Medication reconciliation compares a best possible medication history from at least two sources with current orders at admission, at discharge, and at every clinic visit, and it records the last dose taken of high-risk drugs.

Amiodarone raises digoxin levels and warfarin effect, so digoxin doses are commonly cut by about half and INR is checked more often when amiodarone starts.

Serum digoxin concentration is drawn at least 6 to 8 hours after a dose, with a heart failure target of 0.5 to 0.9 ng/mL.

Potassium supplements should be reassessed whenever an MRA or ARNI is started or a loop diuretic dose is lowered, because the combination can cause hyperkalemia.

Statins are indicated for atherosclerotic disease or risk-based prevention, not for heart failure alone, and simvastatin is limited to 20 mg daily with amiodarone because of myopathy risk.

Last updated: September 2026

Why Medication Safety Is Part of Implementation

A typical patient with heart failure takes many medicines from several prescribers. The four GDMT pillars are only part of the list: diuretics, potassium and magnesium supplements, statins, anticoagulants, antiplatelets, antiarrhythmics, nitrates, diabetes drugs, and over-the-counter products are common. The CHFN content outline expects the nurse to administer these agents safely, check electrolytes and drug levels, watch for interactions and adverse effects, and complete medication reconciliation at every transition.

Medication Reconciliation at Admission, Discharge, and Appointments

Medication reconciliation is the process of creating the most accurate list of what the patient actually takes and comparing it with what is ordered, so that omissions, duplications, dosing errors, and interactions are caught and resolved. The Joint Commission includes it in its National Patient Safety Goals.

Admission: Build the Best Possible Medication History

Use at least two sources : patient and caregiver interview, pill bottles (brown-bag review), pharmacy fill history, outpatient records, and nursing facility medication records.

Ask specifically about over-the-counter products (NSAIDs, decongestants, effervescent antacids), herbal supplements, inhalers, eye drops, patches, samples, and medicines taken "as needed."

Record the dose, frequency, and last dose taken . The last dose matters for the 36-hour ACE inhibitor to ARNI washout, anticoagulant timing before procedures, SGLT2 inhibitor holds before surgery, and interpreting a digoxin level.

Ask how the patient actually takes each drug. "Twice daily" on the label may be "once, when I remember" at home.

Discharge: Reconcile Three Lists

Compare the pre-admission list , the inpatient orders , and the discharge plan . Every medicine should be explicitly labeled new, changed, continued, or stopped .

Make sure stopped drugs leave the home supply. Classic failures are a patient restarting lisinopril at home after being switched to sacubitril/valsartan, or resuming an NSAID or diltiazem that was stopped in the hospital.

Confirm that new prescriptions can be filled (prior authorization, copay, pharmacy stock), and use teach-back for each change.

Send the reconciled list to the next clinician, home health agency, or skilled nursing facility.

Clinic and Home Visits

Repeat a brown-bag review at follow-up. Look for changes made by other prescribers, refill gaps, new OTC products, and duplicate bottles of the same drug under brand and generic names.

  • Discrepancy Type Heart Failure Example Risk
  • Omission MRA or SGLT2 inhibitor not restarted after a procedure Lost GDMT benefit
  • Duplication Lisinopril at home plus sacubitril/valsartan Angioedema

Wrong formulation or dose Metoprolol tartrate substituted for metoprolol succinate Unproven therapy, dosing errors

  • Unintended continuation NSAID or non-dihydropyridine calcium channel blocker Fluid retention, worsening HFrEF
  • Additive interaction Spironolactone plus potassium chloride plus trimethoprim Hyperkalemia
  • Other Frequently Prescribed Agents

Agent Class Role in the Heart Failure Patient Key Nursing Monitoring

Electrolyte supplements (potassium chloride, magnesium) Replace diuretic losses; keep potassium 4.0-5.0 mEq/L and magnesium normal Reassess when an MRA or ARNI starts, the diuretic dose falls, or kidney function worsens; oral magnesium can cause diarrhea

Statins Atherosclerotic disease, diabetes, or risk-based prevention (not for heart failure alone) Muscle symptoms, drug interactions; simvastatin maximum 20 mg daily with amiodarone

Anticoagulants (DOACs, warfarin, heparins) Atrial fibrillation, LV thrombus, venous thromboembolism, mechanical valves, LVAD Bleeding, dose adjustment for kidney function and weight (DOACs), INR 2.0-3.0 for most warfarin indications

Antiplatelets (aspirin, P2Y12 inhibitors) Coronary disease, recent stents GI bleeding; avoid adding to an anticoagulant unless there is a clear indication, and keep combined therapy as short as the cardiology plan allows

Antiarrhythmics (amiodarone, dofetilide) Rhythm control in HFrEF Amiodarone: thyroid and liver tests about every 6 months, lung and eye symptoms, many interactions. Dofetilide: in-hospital start for at least 3 days with QTc and creatinine clearance checks

Nitrates (sublingual nitroglycerin, isosorbide dinitrate) Angina; preload reduction with hydralazine Headache, hypotension; never with PDE-5 inhibitors

Iron Iron deficiency (see section 7.3) IV iron preferred; watch for hypophosphatemia with ferric carboxymaltose

Serum Electrolytes and Drug Levels

Test When to Check Target or Action

Potassium and creatinine Baseline, 1 to 2 weeks after starting or increasing an ACEi, ARB, ARNI, or MRA, then periodically and during illness Potassium 4.0-5.0 mEq/L; creatinine rise up to about 30% can be expected

Magnesium With loop or thiazide diuretics, digoxin, and QT-prolonging drugs Keep in the normal range; low magnesium makes hypokalemia hard to correct

Sodium After adding metolazone or a thiazide, and in advanced heart failure Falling sodium prompts diuretic and fluid review

Digoxin level At least 6 to 8 hours after a dose; after dose changes, kidney decline, or an interacting drug 0.5 to 0.9 ng/mL

  • INR Warfarin therapy, more often after antibiotics or amiodarone Usually 2.0 to 3.0
  • QTc Dofetilide, amiodarone, and other QT-prolonging drugs Hold or adjust per protocol when QTc is prolonged

TSH and liver tests Amiodarone at baseline and about every 6 months Treat thyroid dysfunction, which can worsen heart failure or arrhythmias

Monitoring for Therapeutic Effects, Interactions, and Side Effects

Therapeutic effects are checked with the same data used every visit: weight trend and urine output for diuretics, heart rate and blood pressure for beta-blockers and vasodilators, NYHA class and KCCQ for symptom benefit, and potassium, creatinine, and natriuretic peptide trends for safety and response.

High-Yield Interactions

ACE inhibitor plus ARNI: angioedema; separate by at least 36 hours.

MRA or RAAS inhibitor plus potassium supplements, salt substitutes, trimethoprim, or NSAIDs: hyperkalemia.

Amiodarone plus digoxin: digoxin level rises; the dose is commonly reduced by about half and the level rechecked.

Amiodarone plus warfarin: INR rises over weeks; warfarin often needs a lower dose and closer INR checks.

Nitrates plus PDE-5 inhibitors: severe hypotension (contraindicated); vericiguat plus PDE-5 inhibitors is not recommended.

Loop diuretic plus metolazone: hypokalemia, hyponatremia, and volume depletion.

Dofetilide plus certain drugs (for example, hydrochlorothiazide, trimethoprim, verapamil): contraindicated because dofetilide levels or QT risk rise.

SGLT2 inhibitor plus insulin or a sulfonylurea: hypoglycemia risk; the diabetes regimen may need adjustment.

Clinical Case Scenario: Reconciliation Finds Three Problems

A 76-year-old man with HFrEF is admitted with atrial fibrillation and rapid ventricular response. His discharge summary from 2 months ago lists sacubitril/valsartan, metoprolol succinate, spironolactone, furosemide 40 mg daily, and digoxin 0.125 mg daily. The nurse performs a brown-bag review with his daughter and checks pharmacy fill data.

He is still taking lisinopril 10 mg from an old bottle in addition to sacubitril/valsartan. The team stops both, observes the 36-hour washout, and restarts only the ARNI.

He takes potassium chloride 20 mEq daily , prescribed years ago before spironolactone was added; potassium is 5.3 mEq/L. The supplement is stopped.

Cardiology starts amiodarone for rhythm control. The nurse flags the digoxin interaction, the digoxin dose is reduced, and a level is planned several days later, drawn at least 6 hours after the dose.

At discharge, the nurse gives a reconciled list marked new, changed, continued, and stopped, removes the old bottles with the daughter, and confirms a 7-day appointment with labs.

CHFN Exam Traps & Clinical Pearls

Exam Trap: A medication list copied from the last discharge summary is not reconciliation. The correct answer compares at least two sources with what the patient actually takes.

Clinical Pearl: When a new antiarrhythmic is added, ask "What does this do to digoxin, warfarin, the QT interval, and the statin dose?" before the first dose is given.

Exam Trap: Statins do not treat heart failure itself. Choose a statin for coronary disease or risk-based prevention, not because LVEF is low.